Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Curie-Cancer and Sanofi Cooperate in Research on Ovarian Cancer

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
Preclinical program of translational research tasked with identifying new target proteins.

Sanofi and the Curie Institute, through its Curie-Cancer partnership under the Institut Carnot label, today announce the establishment of a three-year research collaboration to identify new therapeutic targets for the development of treatments for ovarian cancer.

The aim of the collaboration between Sanofi and Curie-Cancer is to revisit the basic biology of this type of cancer through a translational research approach. The Institut Curie has a large collection of cryopreserved tumor samples that are well characterized clinically, histologically and biologically. These can be analyzed to identify biological targets relevant to the effective treatment of certain types of cancer. Through this collaboration, Sanofi and Curie-Cancer expect to gain a better understanding of the molecular alterations that characterize many types of ovarian cancer, thereby enabling effective new drugs to be designed.

"We hope this type of long-term collaboration will ultimately open up perspectives for new therapeutic options for women with this disease. It will combine the accumulated knowledge on ovarian cancer gathered over many years by oncologists and biologists at the Institut Curie with the expertise of researchers from Sanofi's research and product development teams," said Dr. Debasish Roychowdhury, senior vice president and head of Sanofi Oncology. "Established under the Aviesan[1] partnership, this research agreement is a good example of translational research involving French scientific excellence."

"It is currently hard to tackle ovarian cancer. There are very few drugs available. We are very happy to collaborate with Sanofi to potentially provide our patients with additional therapeutic solutions. Sanofi's expertise in the selection of therapeutic targets is complementary to the know-how and technology platforms developed at the Institut Curie," said Damien Salauze, director of Curie-Cancer.

Using technology platforms developed at the Institut Curie by scientific teams led by Dr. Xavier Sastre-Garau and Dr. Sergio Roman-Roman, this program will make it possible to sequence molecules expressed by the tumor genome, compare the sequences of those obtained with non-tumor tissues from the same patients and then clarify and validate the nature of the molecular alterations that are identified. Sanofi's expertise in the selection of therapeutic targets will then guide an assessment of the tumor's ability to be inhibited or stimulated by drugs.

Ovarian cancer is still difficult to treat, despite recent advances. The main risk factor is advancing age, as well as a known hereditary factor in 5-10 per cent of cases. They are most often diagnosed late. The current therapeutic strategy of combining surgery and chemotherapy is effective, but relapses are frequent and the condition gradually becomes resistant to medical treatment.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Curie-Cancer and DNA Therapeutics Partner in the Fight Against Cancers
Their clinical and translational research program has developed Dbait molecules now in Phase I clinical trial in patients with advanced melanoma.
Thursday, March 06, 2014
Curie-Cancer and Servier Continue a Renewed Partnership in Cancer Research
Their joint aim is to identify new therapeutic targets in ‘triple negative’ breast cancers.
Wednesday, January 29, 2014
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!